Laura Mezquita

Grupo de investigación

Genómica traslacional y terapias dirigidas en tumores sólidos Junior researcher (R2B)

lmezquita@clinic.cat 0000-0003-0936-7338

Publicaciones destacadas

Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

Autores:
Auclin, E; Benitez-Montanez, J; Tagliamento, M; Parisi, F; Gorria, T;

(...)

Arasanz, H; Rochand, A; Besse, B; Routy, B; Mezquita, L.

Referencia: Lung Cancer 2023.
Effects of spatial variation in dose delivery: what can we learn from radon-related lung cancer studies?

Autores:
Madas, BG; Boei, J; Fenske, N; Hofmann, W; Mezquita, L;

Referencia: Radiation And Environmental Biophysics 2022.
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Autores:
Mezquita, L; Preeshagul, I; Auclin, E; Saravia, D; Hendriks, L;

(...)

Cassard, L; Lopes, G; Chaput, N; Arbour, K; Besse, B.

Referencia: European Journal Of Cancer 2021.
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer

Autores:
Ortiz-Cuaran S; Mezquita L; Swalduz A; Aldea M; Mazieres J;

(...)

Perol M; Besse B; Blay JY; Saintigny P; Planchard D .

Referencia: Clinical Cancer Research 2020.
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

Autores:
Mezquita L.; Jové M.; Nadal E.; Kfoury M.; Morán T.;

(...)

Capellà G.; Rouleau E.; Lázaro C.; Caron O.; Besse B..

Referencia: Journal Of Thoracic Oncology 2020.
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer

Autores:
Mezquita L; Swalduz A; Jovelet C; Ortiz-Cuaran S; Howarth K;

(...)

Massard C; Pérol M; Friboulet L; Besse B; Saintigny P .

Referencia: Jco Precision Oncology 2020.
Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients

Autores:
Mezquita L; Benito A; Ruano-Raviña A; Zamora J; Olmedo ME;

(...)

Hernanz R; Cabañero A; Auclin E; Carrato A; Garrido P.

Referencia: Clinical Lung Cancer 2019.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Autores:
Mezquita, L; Auclin, E; Ferrara, R; Charrier, M; Remon, J;

(...)

Lahmar, J; Adam, J; Chaput, N; Soria, JC; Besse, B.

Referencia: Jama Oncology 2018.

Proyectos destacados

Estudio EXPOS: Exposoma y medicina de precisión en pacientes con cáncer portadores de fusiones oncogénicas: entendiendo el papel de los carcinógenos y su implicación

Investigador/a principal: Laura Mezquita Pérez

Duración: 01/01/2024
Exposome & Precision Medicine in lung Cancer: understanding the role of carcinogens in clinical care

Investigador/a principal: Laura Mezquita Pérez

Duración: 01/01/2024
Impact of circulating neutrophils and tumor-associated neutrophils (TAN) in untreated advanced NSCLC treated with inmunotherapy and /or chemotherapy

Investigador/a principal: Laura Mezquita

Financiador: SEOM (Socieadad Española de Oncología Médica)

Duración: 31/10/2021

Laura Mezquita

Grupo de investigación

Publicaciones destacadas

Proyectos destacados

Estudio EXPOS: Exposoma y medicina de precisión en pacientes con cáncer portadores de fusiones oncogénicas: entendiendo el papel de los carcinógenos y su implicación

Exposome & Precision Medicine in lung Cancer: understanding the role of carcinogens in clinical care

Impact of circulating neutrophils and tumor-associated neutrophils (TAN) in untreated advanced NSCLC treated with inmunotherapy and /or chemotherapy

Suscríbete a la Newsletter del Clínic